<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The clinical course of cerebral sinus-<z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> (CSVT) is largely unknown because prospective studies with a long follow-up and with the goal to assess <z:mp ids='MP_0005048'>thrombosis</z:mp> recurrence rate and predisposing factors for recurrence are lacking </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS AND RESULTS: One hundred forty-five patients with a first CSVT were followed up for a median of 6 years after discontinuation of <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> treatment </plain></SENT>
<SENT sid="2" pm="."><plain>End points were recurrent CSVT or other clinical manifestations of venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>CSVT recurred in 5 patients (3%) and other manifestations of venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> (<z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> of the lower limbs or <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo>) were seen in 10 additional patients (7%), for a recurrence rate of 2.03 per 100 person-years (95% confidence interval, 1.16 to 3.14) for <z:hpo ids='HP_0000001'>all</z:hpo> manifestations of venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> and 0.53 per 100 person-years (95% confidence interval, 0.16 to 1.10) for CSVT </plain></SENT>
<SENT sid="4" pm="."><plain>Nearly half of the recurrences occurred within the first year after discontinuation of <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Risk factors for <z:hpo ids='HP_0004850'>recurrent venous thrombosis</z:hpo> were male sex (adjusted hazard ratio, 9.66; 95% confidence interval, 2.86 to 32.7) and, for thromboses other than CSVT, severe <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> resulting from antithrombin, protein C, <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">protein S deficiency</z:e>, anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibodies, or combined abnormalities (adjusted hazard ratio, 4.71; 95% confidence interval, 1.34 to 16.5) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: The risk of recurrent CSVT is low and is higher in the first year after discontinuation of <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> treatment and among men </plain></SENT>
<SENT sid="7" pm="."><plain>Mild <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> abnormalities are not associated with recurrent CSVT, but severe <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> entails an increased risk of <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> of the lower limbs or <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> </plain></SENT>
</text></document>